Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 30:8:2333794X211048738.
doi: 10.1177/2333794X211048738. eCollection 2021.

The Acceptance Rate Toward COVID-19 Vaccine in Africa: A Systematic Review and Meta-analysis

Addisu Dabi Wake  1
Affiliations
Review

The Acceptance Rate Toward COVID-19 Vaccine in Africa: A Systematic Review and Meta-analysis

Addisu Dabi Wake. Glob Pediatr Health. .

Abstract

Background: The Coronavirus Disease 2019 (COVID-19) pandemic remains serious public issue. COVID-19 vaccine is a vital strategy to prevent this critical pandemic. However, unwillingness to take this vaccine are key barriers to manage the COVID-19 pandemic. The control of this pandemic will depend principally on the people acceptance of COVID-19 vaccine. Therefore, this systematic review and meta-analysis was intended to determine the acceptance rate toward COVID-19 vaccine in Africa. Methods: African Journals OnLine, PubMed, Cochrane Review, HINARI, EMBASE, Google Scholar, Web of Science, and Scopus were used to retrieve related articles. The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines were used for this study. Random-effect model, a funnel plot, Egger's test, I 2 statistic, subgroup analysis was done. The study was performed by using a STATA version 11 statistical software. Results: A total of 22 studies with 33,912 study participants were included in this systematic review and meta-analysis. From this finding, the pooled prevalence of acceptance toward COVID-19 vaccine among adults in Africa was 48.93% (95% CI: [39.49, 58.37]). The subgroup analysis revealed that the pooled prevalence of COVID-19 vaccine acceptance among adults in Africa was highest (66.03%, 95% CI [62.84, 69.22]) in Southern Africa, and Lowest (24.28%, 95% CI [3.26, 45.30]) in Northern Africa. Conclusion: This study showed that the estimate of the pooled prevalence of acceptance toward COVID-19 vaccine among adults in Africa was very low. All concerned bodies should be actively involved to improve the acceptance rate of COVID-19 vaccine.

Keywords: Africa; COVID-19; acceptance; meta-analysis; systematic review; vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PRISMA Flowchart diagram of the study selection for systematic review and meta-analysis on the acceptance toward COVID-19 vaccine in Africa.
Figure 2.
Figure 2.
Funnel plot with 95% confidence limits of the pooled prevalence of acceptance toward COVID-19 vaccine among adults in Africa.
Figure 3.
Figure 3.
The results of sensitivity analysis of 22 studies conducted on the acceptance toward COVID-19 vaccine among adults in Africa.
Figure 4.
Figure 4.
Forest plot of pooled prevalence of acceptance toward COVID-19 vaccine among adults in Africa.
Figure 5.
Figure 5.
Subgroup analysis by subregion on the pooled prevalence of acceptance toward COVID-19 vaccine among adults in Africa.
Figure 6.
Figure 6.
Subgroup analysis by year of publication on the pooled prevalence of acceptance toward COVID-19 vaccine among adults in Africa.
See this image and copyright information in PMC

References

    1. Lotfi M, Hamblin MR, Rezaei N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020;508:254-266. doi:10.1016/j.cca.2020.05.044 - DOI - PMC - PubMed
    1. Jin Y, Yang H, Ji W, et al.. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:372. doi:10.3390/v12040372 - DOI - PMC - PubMed
    1. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55:105948. doi:10.1016/j.ijantimicag.2020.105948 - DOI - PMC - PubMed
    1. Shanafelt T, Ripp J, Trockel M. Understanding and addressing sources of anxiety among health care professionals during the COVID-19 pandemic. JAMA. 2020;323(21):2133-2134. doi:10.1001/jama.2020.5893 - DOI - PubMed
    1. Dariya B, Nagaraju GP. Understanding novel COVID-19: its impact on organ failure and risk assessment for diabetic and cancer patients. Cytokine Growth Factor Rev. 2020;53:43-52. doi:10.1016/j.cytogfr.2020.05.001 - DOI - PMC - PubMed

LinkOut - more resources